Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT9EQUY)

DTT Name	Melanoma-associated antigen 4 (MAGEA4)
Synonyms	MAGE4; MAGE-X2 antigen; MAGE-X2; MAGE-41 antigen; MAGE-41; MAGE-4 protein; MAGE-4 antigen; Cancer/testis antigen 1.4; CT1.4
Gene Name	MAGEA4
DTT Type	Clinical trial target	[1]
BioChemical Class	Melanoma associated antigen
UniProt ID	MAGA4_HUMAN
TTD ID	T12097
3D Structure	Download 2D Sequence (FASTA) Download 3D Structure (PDB) Download
Sequence	MSSEQKSQHCKPEEGVEAQEEALGLVGAQAPTTEEQEAAVSSSSPLVPGTLEEVPAAESA GPPQSPQGASALPTTISFTCWRQPNEGSSSQEEEGPSTSPDAESLFREALSNKVDELAHF LLRKYRAKELVTKAEMLERVIKNYKRCFPVIFGKASESLKMIFGIDVKEVDPASNTYTLV TCLGLSYDGLLGNNQIFPKTGLLIIVLGTIAMEGDSASEEEIWEELGVMGVYDGREHTVY GEPRKLLTQDWVQENYLEYRQVPGSNPARYEFLWGPRALAETSYVKVLEHVVRVNARVRI AYPSLREAALLEEEEGV
Function	Not known, though may play a role in embryonal development and tumor transformation or aspects of tumor progression.

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

3 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ADP-A2M4	DMRYH3M	Synovial sarcoma	2B5A	Phase 2	[2]
Afamitresgene autoleucel	DM1GR4M	Soft tissue sarcoma	2B57	Phase 2	[3]
CAR-T cells targeting MAGE-A4	DMUBEX4	Lung cancer	2C25.0	Phase 1/2	[1]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT03356808) Antigen-specific T Cells Against Lung Cancer
2	Clinical pipeline report, company report or official report of Adaptimmune.
3	Autologous T cell therapy for MAGE-A4(+) solid cancers in HLA-A*02(+) patients: a phase 1 trial. Nat Med. 2023 Jan;29(1):104-114.